Leerink Partnrs Has Optimistic Outlook of Humana Q3 Earnings

Key Points

• Leerink Partners has significantly increased its Q3 2025 EPS estimate for Humana from $1.63 to $2.81, reflecting a strong optimistic outlook for the insurance provider's earnings.
• Humana reported Q2 earnings of $6.27 EPS, missing the consensus estimate of $6.32, but achieved better-than-expected revenue of $32.39 billion.
• Seventeen analysts rate Humana's stock as "Hold," with a current consensus target price of $281.62, indicating cautious sentiment among market analysts.

Humana Inc. (NYSE:HUM - Free Report) - Analysts at Leerink Partnrs upped their Q3 2025 EPS estimates for Humana in a research report issued to clients and investors on Wednesday, July 30th. Leerink Partnrs analyst W. Mayo now anticipates that the insurance provider will post earnings per share of $2.81 for the quarter, up from their prior forecast of $1.63. The consensus estimate for Humana's current full-year earnings is $16.47 per share. Leerink Partnrs also issued estimates for Humana's Q4 2025 earnings at ($3.40) EPS, Q3 2026 earnings at $2.20 EPS, Q4 2026 earnings at ($4.32) EPS and FY2028 earnings at $35.72 EPS.

Humana (NYSE:HUM - Get Free Report) last released its quarterly earnings results on Wednesday, July 30th. The insurance provider reported $6.27 earnings per share for the quarter, missing the consensus estimate of $6.32 by ($0.05). The company had revenue of $32.39 billion during the quarter, compared to the consensus estimate of $31.85 billion. Humana had a net margin of 1.28% and a return on equity of 13.67%. The business's revenue was up 9.6% on a year-over-year basis. During the same quarter last year, the firm earned $6.96 EPS.

Several other analysts also recently commented on HUM. Piper Sandler cut their price objective on shares of Humana from $288.00 to $272.00 and set a "neutral" rating on the stock in a research report on Thursday. Wells Fargo & Company set a $348.00 price objective on shares of Humana in a research report on Friday, July 18th. Guggenheim assumed coverage on Humana in a research report on Wednesday, April 9th. They issued a "buy" rating and a $326.00 target price for the company. Barclays set a $275.00 target price on Humana and gave the stock an "equal weight" rating in a research report on Thursday. Finally, Mizuho boosted their target price on Humana from $305.00 to $316.00 and gave the stock an "outperform" rating in a research report on Wednesday, April 9th. Seventeen research analysts have rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $281.62.

Humana Stock Performance

NYSE:HUM opened at $247.19 on Monday. The company has a quick ratio of 1.95, a current ratio of 1.95 and a debt-to-equity ratio of 0.69. The stock has a market cap of $29.73 billion, a P/E ratio of 18.97, a price-to-earnings-growth ratio of 1.45 and a beta of 0.44. The firm's fifty day simple moving average is $235.09 and its 200 day simple moving average is $254.92. Humana has a twelve month low of $206.87 and a twelve month high of $382.72.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in HUM. Cary Street Partners Investment Advisory LLC boosted its stake in Humana by 63.9% in the 1st quarter. Cary Street Partners Investment Advisory LLC now owns 118 shares of the insurance provider's stock worth $31,000 after purchasing an additional 46 shares during the period. Riverview Trust Co bought a new position in Humana in the 1st quarter worth approximately $34,000. Garde Capital Inc. bought a new position in Humana in the 1st quarter worth approximately $36,000. Zions Bancorporation National Association UT bought a new position in Humana in the 1st quarter worth approximately $37,000. Finally, Transce3nd LLC bought a new position in Humana in the 4th quarter worth approximately $38,000. 92.38% of the stock is currently owned by institutional investors.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.